Loading data for COGT — first visit, this takes a few seconds.

Alerta

Cogent Biosciences Inc. (COGT)

NasdaqGS: COGT · Precio en tiempo real · USD

35.31

-1.54 (-4.18%)

Al cierre: Aug 20, 2026, 3:59 PM

35.55

+0.68%

Premercado: 5:55 AM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-4.18% (1D)

Precio de compra	26.05
Capitalización de mercado	6.13B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-377.18M
	0.33
	-2.07
	n/a
	-31.92
P/B (TTM)	12.96
P/S (TTM)	n/a
Fecha de resultados	Nov 3, 2026

Precio de venta	44.92
Volumen	1,943,599
Volumen medio (20D)	2,488,873
Abierto	36.31
Anterior Cerrar	36.85
Rango del día	34.96 - 36.70
Rango de 52 semanas	11.60 - 43.73
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de COGT

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Mar 29, 2018

Empleados 258

Bolsa de Valores NasdaqGS

Símbolo bursátil COGT

Sitio web https://www.cogentbio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Cogent Biosciences fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -328.94M, un aumento de 28.56%.

Estados financieros

Sorpresa de resultados

Cogent Biosciences ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.52 supera las estimaciones en 0.04, con 1.89% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Cogent Biosciences Inc. publique sus resultados el Nov 3, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

1 mes hace · Insider Monkey

Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 10 affordable biotech stocks to buy right now. On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for b...

2 meses hace · Insider Monkey

Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 12, Cogent Biosciences, Inc. (NASDAQ:COGT) presented early-stage precli...

2 meses hace · MT Newswires

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

Cogent Biosciences (COGT) Bezuclastinib showed "rapid and deep" clinical benefit and met primary and

2 meses hace · Simply Wall St.

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

Cogent Biosciences recently reported detailed primary analysis data from its PEAK Phase 3 trial, showing that bezuclastinib plus sunitinib significantly improved progression-free survival and objectiv...

Página 1 de 2

Cogent Biosciences Inc. (COGT)